282 related articles for article (PubMed ID: 29185119)
41. Gain-of-function p53 mutant with 21-bp deletion confers susceptibility to multidrug resistance in MCF-7 cells.
Tsou SH; Hou MH; Hsu LC; Chen TM; Chen YH
Int J Mol Med; 2016 Jan; 37(1):233-42. PubMed ID: 26572087
[TBL] [Abstract][Full Text] [Related]
42. Inhibition of KLF4 by Statins Reverses Adriamycin-Induced Metastasis and Cancer Stemness in Osteosarcoma Cells.
Li Y; Xian M; Yang B; Ying M; He Q
Stem Cell Reports; 2017 Jun; 8(6):1617-1629. PubMed ID: 28552603
[TBL] [Abstract][Full Text] [Related]
43. EIF5A2 is a novel chemoresistance gene in breast cancer.
Liu Y; Du F; Chen W; Yao M; Lv K; Fu P
Breast Cancer; 2015 Nov; 22(6):602-7. PubMed ID: 24638963
[TBL] [Abstract][Full Text] [Related]
44. Targeted silencing of elongation factor 2 kinase suppresses growth and sensitizes tumors to doxorubicin in an orthotopic model of breast cancer.
Tekedereli I; Alpay SN; Tavares CD; Cobanoglu ZE; Kaoud TS; Sahin I; Sood AK; Lopez-Berestein G; Dalby KN; Ozpolat B
PLoS One; 2012; 7(7):e41171. PubMed ID: 22911754
[TBL] [Abstract][Full Text] [Related]
45. Mithramycin A sensitizes therapy-resistant breast cancer stem cells toward genotoxic drug doxorubicin.
Saha S; Mukherjee S; Mazumdar M; Manna A; Khan P; Adhikary A; Kajal K; Jana D; Sa G; Mukherjee S; Sarkar DK; Das T
Transl Res; 2015 May; 165(5):558-77. PubMed ID: 25468484
[TBL] [Abstract][Full Text] [Related]
46. PRMT5 Is a Critical Regulator of Breast Cancer Stem Cell Function via Histone Methylation and FOXP1 Expression.
Chiang K; Zielinska AE; Shaaban AM; Sanchez-Bailon MP; Jarrold J; Clarke TL; Zhang J; Francis A; Jones LJ; Smith S; Barbash O; Guccione E; Farnie G; Smalley MJ; Davies CC
Cell Rep; 2017 Dec; 21(12):3498-3513. PubMed ID: 29262329
[TBL] [Abstract][Full Text] [Related]
47. Reduced miR-128 in breast tumor-initiating cells induces chemotherapeutic resistance via Bmi-1 and ABCC5.
Zhu Y; Yu F; Jiao Y; Feng J; Tang W; Yao H; Gong C; Chen J; Su F; Zhang Y; Song E
Clin Cancer Res; 2011 Nov; 17(22):7105-15. PubMed ID: 21953503
[TBL] [Abstract][Full Text] [Related]
48. Breast tumour cell subpopulations with expression of the MYC and OCT4 proteins.
Litviakov NV; Bychkov VA; Stakheeva MN; Ibragimova MK; Tsyganov MM; Gaptulbarova KA; Tashireva LA; Bondar LN; Garbukov EY; Slonimskaya EM
J Mol Histol; 2020 Dec; 51(6):717-728. PubMed ID: 33037978
[TBL] [Abstract][Full Text] [Related]
49. PRMT5 regulates RNA m6A demethylation for doxorubicin sensitivity in breast cancer.
Wu Y; Wang Z; Han L; Guo Z; Yan B; Guo L; Zhao H; Wei M; Hou N; Ye J; Wang Z; Shi C; Liu S; Chen C; Chen S; Wang T; Yi J; Zhou J; Yao L; Zhou W; Ling R; Zhang J
Mol Ther; 2022 Jul; 30(7):2603-2617. PubMed ID: 35278676
[TBL] [Abstract][Full Text] [Related]
50. Protein arginine methyltransferase 5-mediated epigenetic silencing of IRX1 contributes to tumorigenicity and metastasis of gastric cancer.
Liu X; Zhang J; Liu L; Jiang Y; Ji J; Yan R; Zhu Z; Yu Y
Biochim Biophys Acta Mol Basis Dis; 2018 Sep; 1864(9 Pt B):2835-2844. PubMed ID: 29802960
[TBL] [Abstract][Full Text] [Related]
51. PRMT5-dependent transcriptional repression of c-Myc target genes promotes gastric cancer progression.
Liu M; Yao B; Gui T; Guo C; Wu X; Li J; Ma L; Deng Y; Xu P; Wang Y; Yang D; Li Q; Zeng X; Li X; Hu R; Ge J; Yu Z; Chen Y; Chen B; Ju J; Zhao Q
Theranostics; 2020; 10(10):4437-4452. PubMed ID: 32292506
[TBL] [Abstract][Full Text] [Related]
52. Regulation of stem cells-related signaling pathways in response to doxorubicin treatment in Hs578T triple-negative breast cancer cells.
Tudoran O; Soritau O; Balacescu L; Visan S; Barbos O; Cojocneanu-Petric R; Balacescu O; Berindan-Neagoe I
Mol Cell Biochem; 2015 Nov; 409(1-2):163-76. PubMed ID: 26187676
[TBL] [Abstract][Full Text] [Related]
53. Role of DJ-1 siRNA in reverse sensitivity of breast cancer cells to chemotherapy and its possible mechanism.
Zhang GQ; He C; Tao L; Liu F
Int J Clin Exp Pathol; 2015; 8(6):6944-51. PubMed ID: 26261582
[TBL] [Abstract][Full Text] [Related]
54. CD44hiCD24lo mammosphere-forming cells from primary breast cancer display resistance to multiple chemotherapeutic drugs.
Ji P; Zhang Y; Wang SJ; Ge HL; Zhao GP; Xu YC; Wang Y
Oncol Rep; 2016 Jun; 35(6):3293-302. PubMed ID: 27109463
[TBL] [Abstract][Full Text] [Related]
55. A novel miR-34a target, protein kinase D1, stimulates cancer stemness and drug resistance through GSK3/β-catenin signaling in breast cancer.
Kim do Y; Park EY; Chang E; Kang HG; Koo Y; Lee EJ; Ko JY; Kong HK; Chun KH; Park JH
Oncotarget; 2016 Mar; 7(12):14791-802. PubMed ID: 26895471
[TBL] [Abstract][Full Text] [Related]
56. Circular RNA La-related RNA-binding protein 4 correlates with reduced tumor stage, as well as better prognosis, and promotes chemosensitivity to doxorubicin in breast cancer.
Zhang X; Su X; Guo Z; Jiang X; Li X
J Clin Lab Anal; 2020 Jul; 34(7):e23272. PubMed ID: 32187743
[TBL] [Abstract][Full Text] [Related]
57. Breast cancer patient-derived scaffolds as a tool to monitor chemotherapy responses in human tumor microenvironments.
Leiva MC; Garre E; Gustafsson A; Svanström A; Bogestål Y; Håkansson J; Ståhlberg A; Landberg G
J Cell Physiol; 2021 Jun; 236(6):4709-4724. PubMed ID: 33368325
[TBL] [Abstract][Full Text] [Related]
58. PRMT5 inhibition disrupts splicing and stemness in glioblastoma.
Sachamitr P; Ho JC; Ciamponi FE; Ba-Alawi W; Coutinho FJ; Guilhamon P; Kushida MM; Cavalli FMG; Lee L; Rastegar N; Vu V; Sánchez-Osuna M; Coulombe-Huntington J; Kanshin E; Whetstone H; Durand M; Thibault P; Hart K; Mangos M; Veyhl J; Chen W; Tran N; Duong BC; Aman AM; Che X; Lan X; Whitley O; Zaslaver O; Barsyte-Lovejoy D; Richards LM; Restall I; Caudy A; Röst HL; Bonday ZQ; Bernstein M; Das S; Cusimano MD; Spears J; Bader GD; Pugh TJ; Tyers M; Lupien M; Haibe-Kains B; Artee Luchman H; Weiss S; Massirer KB; Prinos P; Arrowsmith CH; Dirks PB
Nat Commun; 2021 Feb; 12(1):979. PubMed ID: 33579912
[TBL] [Abstract][Full Text] [Related]
59. The PRMT5/WDR77 complex regulates alternative splicing through ZNF326 in breast cancer.
Rengasamy M; Zhang F; Vashisht A; Song WM; Aguilo F; Sun Y; Li S; Zhang W; Zhang B; Wohlschlegel JA; Walsh MJ
Nucleic Acids Res; 2017 Nov; 45(19):11106-11120. PubMed ID: 28977470
[TBL] [Abstract][Full Text] [Related]
60. A miR-26a/E2F7 feedback loop contributes to tamoxifen resistance in ER-positive breast cancer.
Liu J; Li X; Wang M; Xiao G; Yang G; Wang H; Li Y; Sun X; Qin S; Du N; Ren H; Pang Y
Int J Oncol; 2018 Oct; 53(4):1601-1612. PubMed ID: 30066905
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
